MX387753B - Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario. - Google Patents

Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario.

Info

Publication number
MX387753B
MX387753B MX2016009428A MX2016009428A MX387753B MX 387753 B MX387753 B MX 387753B MX 2016009428 A MX2016009428 A MX 2016009428A MX 2016009428 A MX2016009428 A MX 2016009428A MX 387753 B MX387753 B MX 387753B
Authority
MX
Mexico
Prior art keywords
plasma kallikrein
binding proteins
hereditary angioedema
treat hereditary
treat
Prior art date
Application number
MX2016009428A
Other languages
English (en)
Spanish (es)
Other versions
MX2016009428A (es
Inventor
Burt Adelman
Christopher Tenhoor
Daniel J Sexton
Jon A Kenniston
Joseph Biedenkapp
Ryan Faucette
Ryan Iarrobino
Yung Chyung
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2016009428A publication Critical patent/MX2016009428A/es
Publication of MX387753B publication Critical patent/MX387753B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
    • C12Y207/03002—Creatine kinase (2.7.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2016009428A 2014-01-21 2015-01-21 Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario. MX387753B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461929716P 2014-01-21 2014-01-21
US201461944361P 2014-02-25 2014-02-25
US201462021397P 2014-07-07 2014-07-07
PCT/US2015/012212 WO2015112578A1 (en) 2014-01-21 2015-01-21 Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Publications (2)

Publication Number Publication Date
MX2016009428A MX2016009428A (es) 2017-04-13
MX387753B true MX387753B (es) 2025-03-18

Family

ID=53681890

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016009428A MX387753B (es) 2014-01-21 2015-01-21 Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario.
MX2021013665A MX2021013665A (es) 2014-01-21 2016-07-20 Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013665A MX2021013665A (es) 2014-01-21 2016-07-20 Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.

Country Status (18)

Country Link
US (2) US11084884B2 (enExample)
EP (2) EP3096798B1 (enExample)
JP (4) JP6845012B2 (enExample)
KR (4) KR20220107077A (enExample)
CN (2) CN106132442B (enExample)
AU (3) AU2015209481C1 (enExample)
BR (1) BR112016016916B1 (enExample)
CA (1) CA2937329C (enExample)
DK (1) DK3096798T3 (enExample)
EA (1) EA038532B1 (enExample)
ES (1) ES2856076T3 (enExample)
IL (3) IL246864B (enExample)
MX (2) MX387753B (enExample)
NZ (2) NZ761006A (enExample)
PL (1) PL3096798T3 (enExample)
PT (1) PT3096798T (enExample)
WO (1) WO2015112578A1 (enExample)
ZA (2) ZA201605342B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3459564T3 (pl) 2010-01-06 2022-04-19 Takeda Pharmaceutical Company Limited Białka wiążące kalikreinę osocza
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CN111044725B (zh) 2013-01-20 2024-03-29 武田药品工业株式会社 缓激肽介导的病症的评估和治疗
EP3594244A1 (en) 2013-03-15 2020-01-15 Dyax Corp. Anti-plasma kallikrein antibodies
KR102521947B1 (ko) 2013-10-21 2023-04-14 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
AU2014340449B2 (en) 2013-10-21 2019-10-31 Takeda Pharmaceutical Company Limited Diagnosis and treatment of autoimmune diseases
KR20220107077A (ko) 2014-01-21 2022-08-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
MX2017012423A (es) * 2015-03-30 2018-01-26 Dyax Corp Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
KR102698737B1 (ko) * 2015-10-19 2024-08-27 다케다 파머수티컬 컴패니 리미티드 절단된 고분자량 키니노겐의 검출을 위한 면역검정법
KR20250139401A (ko) * 2015-12-11 2025-09-23 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
WO2018053260A1 (en) 2016-09-16 2018-03-22 Dyax Corp. Rna biomarkers for hereditary angioedema
US11815516B2 (en) * 2016-09-16 2023-11-14 Takeda Pharmaceutical Company Limited Protein biomarkers for diseases associated with the contact activation system
SG11202003479TA (en) * 2017-10-18 2020-05-28 Regenxbio Inc Fully-human post-translationally modified antibody therapeutics
EP3719127A4 (en) 2017-12-01 2021-10-20 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE
CA3083970A1 (en) 2017-12-01 2019-06-06 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
KR102756073B1 (ko) 2017-12-01 2025-01-20 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 이중-가닥 올리고뉴클레오티드, 조성물 및 이중-가닥 올리고뉴클레오티드를 포함하는 접합체, 그의 제조 방법 및 그의 용도
US11414665B2 (en) 2017-12-01 2022-08-16 Suzhou Ribo Life Science Co., Ltd. Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
CN118291457A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019128611A1 (en) 2017-12-29 2019-07-04 Suzhou Ribo Life Science Co., Ltd. Conjugates and preparation and use thereof
EP3842534A4 (en) 2018-08-21 2022-07-06 Suzhou Ribo Life Science Co., Ltd. NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE WITH NUCLEIC ACID AND THEIR USE
JP7376952B2 (ja) 2018-09-30 2023-11-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド ｓｉＲＮＡ複合体及びその調製方法と使用
WO2020135673A1 (zh) 2018-12-28 2020-07-02 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
US12163956B2 (en) 2019-02-21 2024-12-10 Takeda Pharmaceutical Company Limited Lateral flow immunoassay for measuring functional C1-esterase inhibitor (C1-INH) in plasma samples
TW202100561A (zh) * 2019-03-14 2021-01-01 美商戴氏公司 血漿胰舒血管素抑制劑及其於治療遺傳性血管水腫發作的用途
CN118256498A (zh) 2019-05-22 2024-06-28 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN113891939B (zh) * 2019-05-24 2024-04-02 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CA3167336A1 (en) 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
WO2021202948A2 (en) * 2020-04-04 2021-10-07 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1987005396A1 (en) 1986-03-03 1987-09-11 Brigham And Women's Hospital A method for evaluating nephrotoxicity
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CA2180950C (en) 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
US5840871A (en) 1997-01-29 1998-11-24 Incyte Pharmaceuticals, Inc. Prostate-associated kallikrein
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
IL161677A0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
US7064107B2 (en) 2002-06-07 2006-06-20 Dyax Corp. Prevention and reduction of blood loss
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1674480A4 (en) 2003-09-04 2007-06-20 Riken ANTIBODY RECOGNIZING THE REGIONAL SECTION CONTROLLING TGF-BETA ACTIVATION
EP1713929A2 (en) 2004-02-03 2006-10-25 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
AU2005271523B2 (en) 2004-08-03 2011-09-15 Dyax Corp. hk1-binding proteins
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2007104541A2 (en) 2006-03-16 2007-09-20 Dyax Corp. Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
EP2051707B1 (en) 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
KR100846354B1 (ko) 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
US8501695B2 (en) * 2007-07-20 2013-08-06 Diamedica, Inc. Tissue kallikrein for the treatment of diseases associated with amyloid protein
JP2010536883A (ja) 2007-08-23 2010-12-02 ジェンザイム・コーポレーション カリクレイン阻害剤を用いた治療
MX2011000071A (es) 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
CN102307594A (zh) * 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
CN101928346B (zh) 2009-07-31 2013-01-16 华中科技大学同济医学院附属同济医院 一种抗人组织激肽释放酶单克隆抗体及其制备
PL3459564T3 (pl) 2010-01-06 2022-04-19 Takeda Pharmaceutical Company Limited Białka wiążące kalikreinę osocza
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
SMT201700515T1 (it) 2011-05-02 2018-01-11 Millennium Pharm Inc Formulazione per anticorpo anti- 4 7
US10316095B2 (en) 2012-02-16 2019-06-11 Santarus, Inc. Antibody formulations
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
KR102658793B1 (ko) 2013-01-20 2024-04-19 다케다 파머수티컬 컴패니 리미티드 pKal 매개 장애의 평가, 검정 및 치료
CN111044725B (zh) 2013-01-20 2024-03-29 武田药品工业株式会社 缓激肽介导的病症的评估和治疗
EP3594244A1 (en) 2013-03-15 2020-01-15 Dyax Corp. Anti-plasma kallikrein antibodies
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
KR102521947B1 (ko) 2013-10-21 2023-04-14 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
KR20220107077A (ko) 2014-01-21 2022-08-01 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
MX2017012423A (es) 2015-03-30 2018-01-26 Dyax Corp Inhibidores de calicreina plasmatica y uso de los mismos para prevenir el ataque del angioedema hereditario.
KR20250139401A (ko) 2015-12-11 2025-09-23 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
BR112019005167A2 (pt) * 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
WO2019048961A1 (en) 2017-09-05 2019-03-14 Bat Call D. Adler Ltd. DIAGNOSIS OF PATHOLOGIES USING INFRASONIC SIGNATURES
WO2020047352A1 (en) 2018-08-30 2020-03-05 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
TW202100561A (zh) 2019-03-14 2021-01-01 美商戴氏公司 血漿胰舒血管素抑制劑及其於治療遺傳性血管水腫發作的用途
CA3167336A1 (en) 2020-01-13 2021-07-22 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack

Also Published As

Publication number Publication date
IL278062B (en) 2022-06-01
US11084884B2 (en) 2021-08-10
ZA202004653B (en) 2022-01-26
NZ723369A (en) 2022-12-23
US12384854B2 (en) 2025-08-12
KR20160122169A (ko) 2016-10-21
JP7164502B2 (ja) 2022-11-01
CN116585468A (zh) 2023-08-15
EP3096798B1 (en) 2020-11-25
CA2937329A1 (en) 2015-07-30
EP3848057A1 (en) 2021-07-14
AU2015209481B2 (en) 2020-07-30
AU2015209481C1 (en) 2020-10-29
CA2937329C (en) 2022-05-31
KR20240049627A (ko) 2024-04-16
EP3096798A1 (en) 2016-11-30
PT3096798T (pt) 2021-02-25
JP2020002171A (ja) 2020-01-09
EP3096798A4 (en) 2017-08-23
PL3096798T3 (pl) 2021-07-26
ES2856076T3 (es) 2021-09-27
IL263669A (en) 2019-01-31
EP3848057B1 (en) 2025-12-10
IL278062A (en) 2020-11-30
AU2015209481A1 (en) 2016-08-25
AU2020244370A1 (en) 2020-10-29
KR20220107077A (ko) 2022-08-01
US20170002094A1 (en) 2017-01-05
ZA201605342B (en) 2020-11-25
BR112016016916A2 (pt) 2018-01-23
IL263669B (en) 2020-10-29
KR102903403B1 (ko) 2025-12-24
JP2017503820A (ja) 2017-02-02
EA038532B1 (ru) 2021-09-10
EA201691470A1 (ru) 2016-12-30
JP2023015087A (ja) 2023-01-31
BR112016016916B1 (pt) 2023-12-19
AU2020244370B2 (en) 2024-03-07
BR112016016916A8 (pt) 2018-05-02
JP6845012B2 (ja) 2021-03-17
CN106132442B (zh) 2023-07-14
US20210087293A1 (en) 2021-03-25
MX2016009428A (es) 2017-04-13
CN106132442A (zh) 2016-11-16
MX2021013665A (es) 2021-12-10
KR102424183B1 (ko) 2022-07-26
NZ761006A (en) 2023-04-28
KR20240033156A (ko) 2024-03-12
IL246864B (en) 2018-12-31
WO2015112578A1 (en) 2015-07-30
JP2024170495A (ja) 2024-12-10
AU2024203436A1 (en) 2024-06-13
DK3096798T3 (da) 2021-03-01

Similar Documents

Publication Publication Date Title
MX387753B (es) Proteínas de unión a calicreína en plasma y usos de las mismas para tratar el angioedema hereditario.
PH12019502724A1 (en) Compositions for modulating c9orf72 expression
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
IL255615A (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
ZA201803661B (en) Compositions and methods for decreasing tau expression
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
IL251759B (en) Compositions and methods for treating insomnia
IL252418B (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
CO6950477A2 (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
DK2914630T3 (da) Hidtil ukendte antigen-bindende proteiner og deres anvendelse som adresseringsprodukt til behandling af kræft
MX2015003701A (es) Composiciones para tratamiento.
IL272246A (en) Compositions and methods for treating galactosemia
IL257764B (en) Methods for treatment of diseases
EA201791538A1 (ru) Способ предотвращения или лечения потери слуха
MX2017005064A (es) Metodos para tratar afecciones oculares.
MX2018012230A (es) Métodos para tratar enfermedades oculares.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
HUE052098T2 (hu) Prohemosztatikus fehérjék vérzés kezelésére
IL252707A0 (en) Compositions and methods for treating diseases and conditions
CY1125266T1 (el) To rad1901 για χρηση στη θεραπεια του καρκινου των ωοθηκων
BR112017026193A2 (pt) agentes de clarificação para bioprocessamento de adsorventes e métodos de produção e uso dos mesmos
IL249483A0 (en) Preparation methods for a novel generation of biological safe klh products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents
MX380683B (es) Lisobactina para su uso en el tratamiento de la mastitis bovina.